STAT3 and ovarian carcinoma: With the advances of both A2B inhibitors (TT‐4, TT‐702, GS‐6201, PBF‐1129, etc.)and STAT3 inhibitors (C188‐9, Napabucasin, GLG‐801, WP‐1066, PCUR‐101, etc.)in the clinic, combination of those drugs with PARP inhibitors may achieve better therapeutic outcomes in ovarian cancers.